IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Diversified Trust Co

Diversified Trust Co lowered its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 27.2% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,343 shares of the company’s stock after selling 502 shares during the quarter. Diversified Trust Co’s holdings in IDEXX Laboratories were worth $725,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Truist Financial Corp raised its stake in shares of IDEXX Laboratories by 2.7% in the 3rd quarter. Truist Financial Corp now owns 49,327 shares of the company’s stock valued at $21,569,000 after purchasing an additional 1,310 shares in the last quarter. Glenmede Trust Co. NA raised its stake in IDEXX Laboratories by 166.7% during the third quarter. Glenmede Trust Co. NA now owns 3,595 shares of the company’s stock valued at $1,572,000 after buying an additional 2,247 shares in the last quarter. Advisors Asset Management Inc. lifted its holdings in IDEXX Laboratories by 9.6% during the 3rd quarter. Advisors Asset Management Inc. now owns 2,007 shares of the company’s stock worth $878,000 after buying an additional 176 shares during the last quarter. Ameriprise Financial Inc. grew its position in shares of IDEXX Laboratories by 51.3% in the 3rd quarter. Ameriprise Financial Inc. now owns 225,150 shares of the company’s stock worth $98,353,000 after acquiring an additional 76,350 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its holdings in shares of IDEXX Laboratories by 31.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 108,756 shares of the company’s stock valued at $47,556,000 after acquiring an additional 26,055 shares during the last quarter. Institutional investors own 87.84% of the company’s stock.

Insider Transactions at IDEXX Laboratories

In related news, Director Bruce L. Claflin sold 200 shares of the business’s stock in a transaction that occurred on Friday, May 17th. The stock was sold at an average price of $540.80, for a total transaction of $108,160.00. Following the sale, the director now owns 161 shares of the company’s stock, valued at $87,068.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 2.18% of the company’s stock.

IDEXX Laboratories Stock Up 0.2 %

IDXX opened at $477.23 on Wednesday. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.57 and a quick ratio of 1.16. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39. The stock’s 50 day moving average price is $501.52 and its 200 day moving average price is $526.04. The stock has a market cap of $39.41 billion, a P/E ratio of 46.21, a P/E/G ratio of 3.97 and a beta of 1.32.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Wednesday, May 1st. The company reported $2.81 earnings per share for the quarter, beating analysts’ consensus estimates of $2.68 by $0.13. The business had revenue of $964.10 million for the quarter, compared to analysts’ expectations of $965.43 million. IDEXX Laboratories had a net margin of 23.26% and a return on equity of 63.66%. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 11.03 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have commented on IDXX. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Friday, June 14th. William Blair reaffirmed an “outperform” rating on shares of IDEXX Laboratories in a report on Tuesday, April 9th. Morgan Stanley dropped their price objective on shares of IDEXX Laboratories from $620.00 to $596.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 14th. Stifel Nicolaus decreased their target price on IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating for the company in a research note on Monday, June 24th. Finally, Barclays lowered their target price on IDEXX Laboratories from $655.00 to $570.00 and set an “overweight” rating for the company in a report on Thursday, May 2nd. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, IDEXX Laboratories currently has a consensus rating of “Moderate Buy” and an average target price of $586.63.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.